ClinicalTrials.gg
CompletedNCT04936048M4AUpdated Apr 4, 2025

Music for Autism (M4A)

An interventional study of Music Therapy and Play therapy in Autism Spectrum Disorder and Autism, sponsored by NORCE Norwegian Research Centre AS. Completed at 2 sites in 2 countries. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NORCE Norwegian Research Centre AS · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The Music for Autism (M4A) trial evaluates the neurobehavioral outcomes of a music therapy (MT) intervention, compared to a matched play therapy (PT) intervention, on social communication skills, brain connectivity and structural brain changes. In a crossover randomised controlled trial (RCT), 80 children with autism across all levels of functioning, aged 6-12 years, undergo a baseline assessment, which includes measurements of social communication, participation, functional connectivity and brain structure. Participants are then randomly allocated to a sequence of interventions (MT-PT or PT-MT) and assessments are taken before and after each intervention period. Both interventions will target common goals and follow the same structure, while at the same time allowing for flexibility in the therapists' approach. It is hypothesized that 12 weeks of intervention through MT, compared to PT, will improve social communication skills, participation, and other relevant mental health outcomes in children with autism spectrum disorder (ASD), as well as regulate resting-state functional over and under-connectivity and increase grey and white matter volume in specified regions. The investigators also expect changes in functional brain connectivity to correlate with behavioural outcome measures, specifically with improved social communication skills.

Read the detailed description

M4A will combine biomedical research with clinical outcome research to investigate if 12 weeks of intervention through MT, compared to PT, improve social communication skills, participation, family quality of life, receptive vocabulary, adaptive behavior, and symptom severity in children with ASD, and if this is accompanied by a change in resting state functional connectivity (rsFC) as well as grey and white matter volume change. Additional mental health outcomes include not only core areas of impairment, but also associated problems such as chronic stress, which is a significant issue for people with ASD; impedes learning; and can be reduced through music, both as an outcome in itself and as a mediator for other health outcomes.

M4A will also investigate if clinical improvement is correlated with an increase of rsFC between auditory and striatal/fronto-motor regions as well as a decrease of rsFC between auditory and visual regions in MT compared to PT. Possible changes in grey/white matter volume will be measured by voxel-based morphometry (VBM) in a whole-brain scan before and after the interventions.

Sample size and power: This study will be powered for an effect size of d=0.34. With a two-sided significance level of 5%, a sample of n=70 will be required to detect the effect with 80% power. Attrition is expected at \<10%; the study will therefore recruit at least 80 participants. More specifically, the investigators expect to find a mean difference of 4.84 (SD=14.24), corresponding to an effect size d=0.34, on the primary outcome. The investigators expect the scores to be correlated within participants by r≥0.50. Sample size to achieve 80% test power was calculated in R.

Treatment fidelity: All sessions will be recorded on video to help ensure and assess treatment fidelity. Fidelity will be rated by 2 raters, who are trained on a manual for assessment of treatment fidelity, on 4 different dimensions: (1.) Program adherence (number of sessions completed; number and types of activities covered, from the therapist's weekly reports); (2.) Process fidelity (delivery of the theoretical concepts of the intervention); (3.) Content fidelity (establishment of a therapeutic relationship between the participant and the therapist, measured using quality of delivery and participant responsiveness as well as the theoretical principles underlying the interventions); (4.) Programme differentiation between MT and PT ("Music was central to this activity").

Statistical analysis of behavioural outcomes will compare change from before to after each intervention within each participant. The intention-to-treat principle will be followed as applicable in a crossover trial: Participants will be analysed in the group to which they were randomised, regardless of whether they actually received the full allocated intervention. The main analysis will include all participants with valid data for both intervention periods; in addition, multiple imputation of missing outcomes will be used as a sensitivity analysis. Tests will use a two-sided 5% significance level. The two main secondary outcomes, participation and quality of life, will be Bonferroni corrected; the remaining secondary outcomes will be exploratory. Analysis software will be R.

Brain connectivity of frontotemporal regions, measured as rsFC from 6 seeds, will be used as the main neuroscientific outcome. The time-series for each of the seeds will be used to generate individual participant-level maps using whole-brain general linear models at baseline and after the interventions. First-level maps will then be entered into the second-level analyses. For comparison after the intervention, the investigators will use ANCOVA with post-intervention rsFC as a dependent variable, and intervention, baseline rsFC, age, and intelligence quotient (IQ) as covariates. Z-scores of parameter estimates will be used to measure connectivity strength. Results will be reported with a 5% significance level adjusted for multiplicity by family-wise error rate. Z-statistics for each participant from the post-intervention rsFC maps will be used in a linear regression model to evaluate correlation between rsFC and behaviour change. Changes in grey and white matter volume will be assessed in a whole-brain scan using VBM, derived from the anatomical T1 image, acquired at the beginning of each fMRI scan. ROIs include the 6 seeds above as well as other areas identified in our previous review (cerebellum, superior temporal sulcus, temporo-parietal area). The investigators will use SPM12 on Matlab for standard preprocessing and analysis of VBM, and CONN for denoising and rsFC analysis.

02

Conditions studied

  • Autism Spectrum Disorder
  • Autism

Browse trials for

Keywords

  • crossover randomised controlled trial
  • music therapy
  • autism spectrum disorder
  • functional connectivity
  • functional magnetic resonance imaging (fMRI)
  • social communication
  • grey and white matter
03

In context

Autistic Disorder Reclassified

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

This study's enrollment of 68 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

NORCE Norwegian Research Centre AS is the lead sponsor of 25 studies on the registry; 3 are open to participants now.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet diagnostic criteria as specified in , Fifth edition (DSM-V) and officially diagnosed with autism spectrum disorder (ASD) by a licensed clinical professional using standardised diagnostic tools (Autism Diagnostic Observation Schedule (ADOS), Autism Diagnostic Interview Revised (ADI-R)).

Exclusion criteria

Exclusion Criteria:

  • Recent or current music therapy
  • Metallic or electronic implants
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Active comparator
    Music therapy/Play therapy

    This sequence of interventions begins with 12 weeks of music therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of play therapy intervention. Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, and interaction. In both interventions, children can choose 4 activities per session using a visual schedule.

    Behavioral: Music Therapy · Behavioral: Play therapy

  • Active comparator
    Play therapy/Music therapy

    This sequence of interventions begins with 12 weeks of play therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of music therapy intervention. Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, interaction. In both interventions, children can choose 4 activities per session using a visual schedule.

    Behavioral: Music Therapy · Behavioral: Play therapy

Interventions

  • BehavioralMusic Therapy

    Music therapy will use rhythmic cues, music instruments (piano, drums, djembe, xylophone, harmonica), songs, and stories accompanied by songs or musical instruments to target common goals.

  • BehavioralPlay therapy

    Play therapy is designed as a play-based active comparison condition to control for factors such as support, therapist attention, positive expectancies, and emotional engagement. It will use verbal interaction, toys (Lego, finger puppets, Play Doh, puzzles), and the same stories as in MT, but without a musical component, to target common goals.

06

What researchers measure

Primary outcomes

  1. Children's Communication Checklist-2

    The Children's Communication Checklist-2 is a measure designed to assess the communication skills of children. The caregiver-report scale measures aspects of pragmatic communication with 70 items across 10 subdomains. The standard general communication composite standard score will be used as a measure of a child's general pragmatics and communication ability. Scores on the general composite of the Children's Communication Checklist-2 have a mean of 100 (SD=15). Higher scores indicate better social-communication skills.

    Time frame: 12 weeks

  2. Brain connectivity of frontotemporal regions

    Brain connectivity of frontotemporal regions will be measured as resting state functional connectivity (rsFC) from 6 seeds, will be used as the main neuroscientific outcome. Seeds will be anatomically defined regions of interest (ROIs) in Montreal Neurological Institute space for the left and right Heschl's gyrus, inferior frontal gyrus, and temporal pole.

    Time frame: 12 weeks

Secondary outcomes

  1. Child and Adolescent Scale of Participation

    The Child and Adolescent Scale of Participation is a caregiver-report scale consisting of 20 ordinal-scaled items across four subdomains (home participation, community participation, school participation, home and community living activities), that assesses participation. The 20 items are rated on a four-point scale: 1=Unable to participate, 2=Very limited, 3=Somewhat limited, 4=Age expected / Full participation. Higher scores mean a better outcome, indicating more participation in general. Minimum-maximum total scores: 25-100.

    Time frame: 12 weeks

  2. Beach Center Family Quality of Life Scale

    The 25 item scale is used to measure several aspects of families' perceived satisfaction in terms of quality of family life under five domains: Family Interaction, Parenting, Emotional Well-being, Physical / Material Well-being, and Disability-Related Support. The scale uses satisfaction as the primary response format. Participants are asked to rate their levels of satisfaction with certain statements on a 5-point scale, where 1 = very dissatisfied, 3 = neither satisfied nor dissatisfied, and 5 = very satisfied. Higher scores mean a better outcome as they indicate more satisfaction with the families' quality of life. Minimum-maximum total scores: 25-125.

    Time frame: 12 weeks

  3. Peabody Picture Vocabulary Test- 4th edition

    The Peabody Picture Vocabulary Test- 4th edition is a measure used to assess receptive (hearing) vocabulary through 228 items (each with a spoken word + 4 pictures). Raw scores are calculated, then converted to standard score equivalents using tables from the manual. The converted scores have a mean of 100 and a standard deviation of 15. Scores from 70 to 85 are considered moderately low, and scores less than 70 are extremely low. Scores from 85 to 115 are considered average. Scores from 115 to 130 are considered moderately high and scores greater than 130 are extremely high. Higher scores indicate better receptive vocabulary.

    Time frame: 12 weeks

  4. Social Responsiveness Scale

    Symptom severity will be assessed through the Social Responsiveness Scale, a 65-item rating scale measuring deficits in social behavior associated with autism. Caregivers rate on a 4-point Likert scale how often a statement has described a child's behavior over the past six months (1=not true to 4=almost always true). Adding all items generates a total score, with higher scores indicating greater severity of social difficulties and other behaviors associated with autism spectrum disorder. Additionally, the Social Responsiveness Scale yields five subscales: social awareness, social communication, social motivation, social cognition, and restricted and repetitive behaviors. Adding the items within each subscale yields a total score for each construct. Minimum- Maximum total score: 65-195.

    Time frame: 12 weeks

  5. Vineland Adaptive Behavior Scales

    The Vineland Adaptive Behavior Scales is a standardized assessment tool that utilizes semi-structured interview to measure adaptive behavior and support the diagnosis of intellectual and developmental disabilities, autism, and developmental delays. The maladaptive behaviours subdomain of the scale is used to identify the presence of behavior problems such as challenging internalizing and externalizing behaviours in children up to age 18. The scale is administered as a semi-structured interview to an informant who knows the child well. VABS v-scale scores have a mean of 15, (SD=3). Three categories are used to convey the degree of maladaptive behaviour in an individual corresponding to v-scale scores- Below 18: Average, 18-20: Elevated, 21-24: Clinically significant.

    Time frame: 12 weeks

  6. Hair cortisol concentration

    Chronic stress will be measured through hair cortisol concentration in the scalp-nearest 3cm segment, reflecting cumulative cortisol secretion over the past 3 months.

    Time frame: 12 weeks

  7. Grey and white matter volume (Structural brain changes)

    Changes in grey and white matter volume will be assessed in a whole-brain scan using voxel-based morphometry (VBM), derived from the anatomical T1 image, acquired at the beginning of each fMRI scan. ROIs include the 6 seedS: left and right Heschl's gyrus, inferior frontal gyrus, and temporal pole), as well as cerebellum, superior temporal sulcus, and temporo-parietal area.

    Time frame: 12 weeks

07

Study locations

2 sites
  • University of Vienna
    Vienna, Austria
  • NORCE Norwegian Research Centre
    Bergen, Norway
08

References and documents

Publications

  • Geretsegger M, Fusar-Poli L, Elefant C, Mossler KA, Vitale G, Gold C. Music therapy for autistic people. Cochrane Database Syst Rev. 2022 May 9;5(5):CD004381. doi: 10.1002/14651858.CD004381.pub4. PubMed 35532041 ↗

Individual participant data

Plan to share: Yes — De-identified clinical and neuroimaging data will be made accessible for re-use by other researchers via platforms such as ENIGMA. We also plan to publish the primary outcome IPD on a public repository such as NSD (www.nsd.no)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Permanent, from the date of publication.

Access criteria: De-identified clinical data will be stored in a publicly available repository (Open Science Foundation, https://osf.io/).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Dec 2024, 40 months.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 40 months is above that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2021
First posted
Jun 23, 2021
StartActual
Aug 1, 2021
Primary completionActual
Dec 17, 2024
CompletionActual
Dec 31, 2024
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04936048
Lead sponsor
NORCE Norwegian Research Centre AS
Collaborators
University of Bergen, University of Vienna
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Aug 1, 2021
Primary completion
Dec 17, 2024
Completion
Dec 31, 2024
Last update
Apr 4, 2025

Study contacts

Christian Gold, PhD
principal investigator · NORCE Norwegian research Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion